Beyond Psilocybin

Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders

Bibliographic Data

ID14676352
AuthorsStanley Wong (0000-0003-0886-9889, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada, corresponding author), An Yi Yu (Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada), Nicholas Fabiano (0000-0002-6873-5105, Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada), Ofer Finkelstein (Centre for Addiction and Mental Health), Aryan Pasricha (Wake Forest University), Brett D M Jones (0000-0003-3248-1059, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada), Joshua D Rosenblat (0000-0002-4773-2191, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada), Daniel M Blumberger (0000-0002-8422-5818, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada), Benoit H Mulsant (0000-0002-0303-6450, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada), Muhammad Ishrat Husain (0000-0001-5771-5750, Centre for Addiction and Mental Health)
Year2024
Volume56
Issue4
Pages513-529
Publication date2024-08-07
Open AccessNo
TypeARTICLE
VenueJournal of Psychoactive Drugs (JOURNAL)
Journal identifiersISSN: 0279-1072 • E-ISSN: 2159-9777
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/02791072.2023.2251133
PMID37615379
OpenAlexW4386116467
LanguageEN
Citations received3
References cited113

There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a "classic" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics remain limited. A comprehensive scoping review on the use of mescaline, ibogaine, ayahuasca, N,N-dimethyltryptamine (DMT), and lysergic acid diethylamide (LSD) in the treatment of mental and substance disorders was conducted. Independent reviewers screened titles, abstracts, and full texts and conducted data extraction. Seventy-seven studies met the inclusion criteria. There were 43 studies of LSD, 24 studies of ayahuasca, 5 studies of DMT, 5 studies of ibogaine, and 5 studies of mescaline. Commonly reported benefits included improved mood and anxiety symptoms, improved insight, reduced substance use, improved relationships, and decreased vegetative symptoms. Commonly reported adverse effects were psychological, neurological, physical, and gastrointestinal in nature. Serious adverse events (homicide and suicide) were reported in published studies of LSD. In conclusion, there is only low-level evidence to support the safety and efficacy of non-psilocybin serotonergic psychedelics in individuals with mental and substance use disorders

Anxiety · Ayahuasca · Hallucinogen · Lysergic acid diethylamide · Mescaline · Mood · Psilocybin · Psychiatry · Serotonergic · Serotonin · Chemical synthesis and alkaloids · Clinical Psychology · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology · Internal Medicine

Tools

Open DOI